Thomas M Schmitt

This inventor holds 18 USPTO granted patents and 11 published patent applications and 6 EPO patents, primarily in Immunotherapy Technologies. Top assignees: Fred Hutchinson Cancer Center, Adaptive Biotechnologies Corporation, Amazon Technologies, Inc.. Active years: 2017-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Thomas M Schmitt. Retrieved from https://idiyas.com/inventor/thomas-m-schmitt

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 (Patent Applications = 11)

% Patents Active = 88.9

EPO Patents = 6 (Patent Applications = 17)

Average Co-Inventor Count = 3.6

ph-index = 2

Forward Citations = 34(Granted Patents)

Company Filing History:

14 out of 309

Fred Hutchinson Cancer Center

patents

2 out of 58

Adaptive Biotechnologies Corporation

patents

2 out of 23,672

Amazon Technologies, Inc.

patents

4. 2 out of 8

Fred Hutchinson Cancer Research Center

patents

5. 1 out of 2,432

University of Illinois

patents

6. 1 out of 2,173

University of Washington

patents

where one patent can have more than one assignee

Years Active: 2017-2026

Loading Chart...

Areas of Expertise:

T-Cell Immunotherapy

High Affinity TCRs

Binding Proteins

Immunomodulatory Proteins

RAS Neoantigens

WT1 Specificity

MAGE-A1 TCRs

Mesothelin Specificity

Merkel Cell Polyomavirus

Human Compatible TCRs

Fusion Proteins

Immunotherapy Applications

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12653886 - T-CELL IMMUNOTHERAPY SPECIFIC FOR WT-1 (2026-06-16),

2. 12595290 - T CELL RECEPTORS SPECIFIC FOR MESOTHELIN AND THEIR USE IN IMMUNOTHERAPY (2026-04-07),

3. 12448430 - High avidity WT1 T cell receptors and uses thereof (2025-10-21),

4. 12365906 - Immunomodulatory fusion proteins and uses thereof (2025-07-22),

5. 12012443 - Immunomodulatory fusion proteins and uses thereof (2024-06-18),

6. 11725210 - Immunomodulatory fusion proteins and uses thereof (2023-08-15),

7. 11534461 - High affinity merkel cell polyomavirus T antigen-specific TCRS and uses thereof (2022-12-27),

8. 11458191 - Binding proteins specific for RAS neoantigens and uses thereof (2022-10-04),

9. 11382954 - Binding proteins specific for RAS neoantigens and uses thereof (2022-07-12),

10. 11041202 - Method of identifying human compatible T cell receptors specific for an antigenic target (2021-06-22),

11. 11034748 - High affinity MAGE-A1-specific TCRs and uses thereof (2021-06-15),

12. 11026969 - High affinity T cell receptors and uses thereof (2021-06-08),

13. 10875904 - Enhanced affinity T cell receptors and methods for making the same (2020-12-29),

14. 10538572 - T cell immunotherapy specific for WT-1 (2020-01-21),

15. 10344075 - Engineered high-affinity human t cell receptors (2019-07-09),

Title: Innovator Spotlight: Thomas M Schmitt - Pioneering Immunomodulatory Fusion Proteins in Seattle, WA

Introduction:

Meet the inventive mind behind cutting-edge immunotherapy solutions, Thomas M Schmitt, based in Seattle, WA. With a remarkable portfolio of 14 patents, he is revolutionizing the field of immunomodulation with his innovative fusion proteins.

Latest Patents:

Thomas M Schmitt's latest patents focus on immunomodulatory fusion proteins designed to enhance immune responses in the treatment of diseases such as cancer and infectious diseases. These fusion proteins contain unique extracellular binding and intracellular signaling domains that trigger modulatory signals in host cells, particularly T cells. By converting inhibitory signals into positive or costimulatory cues, these proteins show promising potential in improving therapeutic outcomes.

Career Highlights:

Having contributed significantly to the field of immunotherapy, Thomas M Schmitt has worked with prestigious institutions like the Fred Hutchinson Cancer Research Center and Fred Hutchinson Cancer Center. His dedication to advancing the understanding and application of immunomodulatory fusion proteins has made him a key figure in the Seattle biotech scene.

Collaborations:

In his groundbreaking work, Thomas M Schmitt has collaborated closely with esteemed peers such as Philip D Greenberg and Aude Georgiana Chapuis. Together, they have pushed the boundaries of immunotherapy, paving the way for new treatment modalities and potentially life-saving interventions.

Conclusion:

Thomas M Schmitt's inventive spirit and relentless pursuit of scientific innovation have positioned him as a trailblazer in the field of immunotherapy. His contributions to developing novel immunomodulatory fusion proteins underscore the transformative power of inventions in shaping the future of healthcare. As he continues to drive progress in the field, the impact of his work promises to revolutionize treatment options for diverse diseases, offering hope to patients worldwide.

Profile summary based on public USPTO records.